Drug Profile
Research programme: small interfering RNA therapeutics - Phio Pharmaceuticals
Alternative Names: ACU-HHY-011; ACU-HTR-028; ACU-XSP-001; OPK-HVB-004; OPK-HVB-010Latest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator OPKO Health
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Hypersensitivity; Inflammation; Wounds
Most Recent Events
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)